Eric Lefkofsky and his team spent the last few years developing Tempus’ underlying technologies. Now Tempus is entering the next phase of its growth by hiring high-caliber leaders to build its team and build its platform, Eric Lefkofsky informs. In addition to its cancer-focused solutions, Tempus offers a suite of products enabling innovation across the patient care continuum, including disease-specific outcome prediction models, patient-specific blood tests, personalization-focused diagnostics, and reference databases.
With services and content serving approximately 70% of biopharmaceuticals R&D costs, it is helping drive the next wave of innovation for biopharmaceutical companies. Eric Lefkofsky adds that at the forefront of cellular health, Tempus has developed a series of crucial intellectual property (IP). This can significantly impact the future of cellular health. Today, Eric Lefkofsky states, more than 800 physicians rely on Tempus’ solutions to support cancer treatment. Approximately one-third of cancer patients will relapse after their initial treatment, and the relapse rate for indolent cancers is approximately 75%.
That means approximately one out of six patients who undergo initial treatment for indolent cancer will relapse. A standard of care cancer treatment plan would remove the tumor and abandon the patient. These people now have an 80% chance of disease recurrence and a 40% chance of dying from their disease. But with the use of Tempus’ products and the robust data they provide to physicians, doctors will be able to treat these patients to the best effect. “The ability to personalize cancer therapy for each patient offers amazing potential to bring great benefit to individuals with advanced cancer,” said Eric Lefkofsky, CEO and Founder of Tempus.
“We are excited to introduce Tempus’ comprehensive, cloud-based cancer diagnostics solution to the global healthcare community, including our collaborators at Foundation Medicine and Center for Personalized Cancer Therapy.” Precision medicine is a growing revolution in oncology and is helping to save thousands of lives each year. As Eric Lefkofsky points out, most new cancer drugs are targeted therapies that work by adjusting a patient’s DNA and mutating it, but many targets are being met by only a small fraction of the population.